InVivoMAb Anti-Human CD137/TNFRSF9 (Iv0099)

Catalog No.

VHG11001

Species reactivity

Human

Host species

Human

Isotype

IgG2, lambda

Clonality

Monoclonal

Target

Tumor necrosis factor receptor superfamily member 9, 4-1BB ligand receptor, CDw137, T-cell antigen 4-1BB homolog, T-cell antigen ILA, CD137, TNFRSF9, CD137, ILA

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q07011

Applications

ELISA, Neutralization

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

Iv0099

Sanhuang Xiexin Decoction ameliorates lipid disorders in obese mice via inducing browning of white adipose tissue and activating brown adipose tissue., PMID:40346591

Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects., PMID:40216443

Anti-CD137 agonist antibody-independent and clinically feasible preparation of tumor-infiltrating lymphocytes from soft tissue sarcoma and osteosarcoma., PMID:40145091

Composition and function of AChR chimeric autoantibody receptor T cells for antigen-specific B cell depletion in myasthenia gravis., PMID:40020066

A humanized anti-b7h3×4-1BB bispecific antibody exerts potent antitumour effects through the activation of innate and adaptive immunity., PMID:39847994

Dual targeting PD-L1 and 4-1BB to overcome dendritic cell-mediated lenalidomide resistance in follicular lymphoma., PMID:39828715

A humanized anti-MSLN×4-1BB bispecific antibody exhibits potent antitumour activity through 4-1BB signaling activation and fc function without systemic toxicity., PMID:39806351

SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137., PMID:39401967

Photothermal therapy co-localized with CD137 agonism improves survival in an SM1 melanoma model without hepatotoxicity., PMID:39225150

Human/mouse CD137 agonist, JNU-0921, effectively shrinks tumors through enhancing the cytotoxicity of CD8+ T cells in cis and in trans., PMID:39178257

Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells., PMID:39053944

Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism., PMID:38988823

Human effector CD8+ T cells with an activated and exhausted-like phenotype control tumour growth in vivo in a humanized tumour model., PMID:38986249

IMT030122, A novel engineered EpCAM/CD3/4-1BB tri-specific antibody, enhances T-cell recruitment and demonstrates anti-tumor activity in mouse models of colorectal cancer., PMID:38878486

Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells., PMID:38798522

Anti-4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade., PMID:38743752

Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma., PMID:38630291

Alleviating iatrogenic effects of paclitaxel via antiinflammatory treatment., PMID:38623630

CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors., PMID:38593226

Editor's Note: In Vivo Persistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB)., PMID:38356444

Reversing cancer immunoediting phases with a tumor-activated and optically reinforced immunoscaffold., PMID:38333614

Anti-PD-L1-Based Bispecific Antibodies Targeting Co-Inhibitory and Co-Stimulatory Molecules for Cancer Immunotherapy., PMID:38257366

M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation., PMID:38091375

ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1., PMID:37796298

A novel 4-1BB/HER2 bispecific antibody shows potent antitumor activities by increasing and activating tumor-infiltrating T cells., PMID:37559991

Chimeric antigen receptor T-cells: Properties, production, and quality control., PMID:37337970

An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity., PMID:37259060

A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity., PMID:37226226

PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer., PMID:37025995

Inclusion of 4-1BB Costimulation Enhances Selectivity and Functionality of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells., PMID:36968221

iRGD-modified memory-like NK cells exhibit potent responses to hepatocellular carcinoma., PMID:36932395

Reducing affinity as a strategy to boost immunomodulatory antibody agonism., PMID:36725933

Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells., PMID:36658341

Age-related Differences in Immune Reactions to SARS-CoV-2 Spike and Nucleocapsid Antigens., PMID:36593041

Growth Hormone Improves Adipose Tissue Browning and Muscle Wasting in Mice with Chronic Kidney Disease-Associated Cachexia., PMID:36499637

The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies., PMID:36343381

Modulation of urelumab glycosylation separates immune stimulatory activity from organ toxicity., PMID:36248847

Development and characterization of a novel human CD137 agonistic antibody with anti-tumor activity and a good safety profile in non-human primates., PMID:36176235

CD137 agonist potentiates the abscopal efficacy of nanoparticle-based photothermal therapy for melanoma., PMID:36089987

Allergen recognition by specific effector Th2 cells enables IL-2-dependent activation of regulatory T-cell responses in humans., PMID:36089900

A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity., PMID:36076251

Fluorophore-conjugated 4-1BB antibody enables early detection of T-cell responses in inflammatory arthritis via NIRF imaging., PMID:36069957

CD137 Regulates Bone Loss via the p53 Wnt/β-Catenin Signaling Pathways in Aged Mice., PMID:35846320

In vivo validation of the switch antibody concept: SPECT/CT imaging of the anti-CD137 switch antibody Sta-MB shows high uptake in tumors but low uptake in normal organs in human CD137 knock-in mice., PMID:35820360

Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers., PMID:35798537

Optimal CD8+ T cell effector function requires costimulation-induced RNA-binding proteins that reprogram the transcript isoform landscape., PMID:35725727

Immune Checkpoint Blockade via PD-L1 Potentiates More CD28-Based than 4-1BB-Based Anti-Carbonic Anhydrase IX Chimeric Antigen Receptor T Cells., PMID:35628256

CD137 Signal Mediates Cardiac Ischemia-Reperfusion Injury by Regulating the Necrosis of Cardiomyocytes., PMID:35419772

c-Met-targeted chimeric antigen receptor T cells inhibit hepatocellular carcinoma cells in vitro and in vivo., PMID:35403606

In vivo imaging with two-photon microscopy to assess the tumor-selective binding of an anti-CD137 switch antibody., PMID:35318394

Document Download

InVivoMAb Anti-Human CD137/TNFRSF9 (Iv0099).pdf